Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(2.74) per share which missed the analyst consensus estimate of $(2.56) by 6.86 percent. This is a 12.76 percent decrease over losses of $(2.43) per share from the same period last year. The company reported quarterly sales of $1.460 million which beat the analyst consensus estimate of $508.625 thousand by 187.05 percent.